Sugi Predict

Sugi Predict / Compounds / SCHEMBL1716735

SCHEMBL1716735

SCHEMBL1716735

CCC(CC)C(CO)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 6/20 0.49
▸ CA2 P00918 6/20 0.49
▸ CA12 O43570 3/20 0.49
▸ CA9 Q16790 3/20 0.49
▸ CA14 Q9ULX7 3/20 0.49
▸ CA1 P00915 5/20 0.46
▸ MMP1 P03956 3/20 0.46
▸ MMP9 P14780 3/20 0.46
▸ MMP13 P45452 3/20 0.46
▸ MMP8 P22894 3/20 0.46
▸ CA3 P07451 1/20 0.46
▸ CA4 P22748 1/20 0.46
▸ CA6 P23280 1/20 0.46
▸ CA5A P35218 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CA13 Q8N1Q1 1/20 0.46
▸ CA5B Q9Y2D0 1/20 0.46
▸ MMP3 P08254 2/20 0.46
▸ MMP7 P09237 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1716737 1.00 MMP2 (0.49) MMP2CA2CA12CA9CA14
SCHEMBL3202961 0.92 S1PR1 (0.46) MMP2CA2CA12CA9CA14
SCHEMBL3179877 0.90 MMP2 (0.44) MMP2CA2CA12CA9CA14
SCHEMBL3186528 0.88 MMP2 (0.42) MMP2CA2CA12CA9CA14
SCHEMBL13750129 0.87 MMP2 (0.41) MMP2CA2CA12CA9CA14
SCHEMBL3178129 0.87 MMP2 (0.41) MMP2CA2CA12CA9CA14
SCHEMBL3186653 0.87 MMP2 (0.41) MMP2CA2CA12CA9CA14
SCHEMBL3198456 0.87 CA2 (0.56) MMP2CA2CA12CA9CA14
SCHEMBL13335267 0.87 CA2 (0.56) MMP2CA2CA12CA9CA14
SCHEMBL3177359 0.87 CA2 (0.56) MMP2CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025043067-A2 PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS FOR THE TREATMENT OF CHRONIC HEART FAILURE CARDURION PHARMACEUTICALS, INC. (US) 2025-02-27 — — WO disclosed
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PFIZER INC. (US) 2024-07-30 — — US disclosed
CN-107787322-B Tricyclic compounds and their use as phosphodiesterase inhibitors 辉瑞大药厂 2023-07-07 — — CN disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 — — US disclosed
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-01-05 — — US disclosed
EP-3766885-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER (US) 2022-05-25 — — EP disclosed
EP-3766885-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Pfizer Inc (US) 2021-01-20 — — EP disclosed
EP-3310784-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. PFIZER (US) 2020-10-07 — — EP disclosed
EP-3253755-B1 NOVEL CYCLOPROPABENZOFURANYL PYRIDOPYRAZINEDIONES PFIZER (US) 2020-08-26 — — EP disclosed
CN-107406445-B Cyclopropylbenzofuranyl pyridopyrazine diones 辉瑞公司 2019-12-24 — — CN disclosed
US-20130053373-A1 Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds BRODNEY MICHAEL AARON (US) 2013-02-28 — — US disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 — — US disclosed
WO-2012172449-A1 LACTAMS AS BETA SECRETASE INHIBITORS PFIZER INC. (US) 2012-12-20 — — WO disclosed
WO-2012131539-A1 NOVEL BICYCLIC PYRIDINONES PFIZER INC. (US) 2012-10-04 — — WO disclosed
US-20120252758-A1 Novel Bicyclic Pyridinones PFIZER INC. 2012-10-04 — — US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 — — US disclosed
EP-2152712-B1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER (US) 2012-01-11 — — EP disclosed
US-7964607-B2 Pyrazolo[3,4-d]pyrimidine compounds PFIZER INC. (US) 2011-06-21 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
US-20090030003-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC 2009-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A MMP2 156/4885CA2 132/4885CA12 2389/4885
US-20120329777-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A MMP2 1149/4885CA2 3345/4885CA12 4275/4885
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A MMP2 1149/4885CA2 3345/4885CA12 4275/4885
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A MMP2 156/4885CA2 132/4885CA12 2389/4885
US-20090030003-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A MMP2 1140/4885CA2 3251/4885CA12 4295/4885
US-20120252758-A1 Novel Bicyclic Pyridinones CYP2B6, CYP2C19, CYP2D6 MMP2 3109/4885CA2 3347/4885CA12 4531/4885
US-20130053373-A1 Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds DPYD, TPMT, QDPR MMP2 4145/4885CA2 2323/4885CA12 4152/4885
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A MMP2 156/4885CA2 132/4885CA12 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.